Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 25

Sort by

Sort Order Select

Journal Articles

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia, David J. McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Jared S. Fowles, Daniel L. Gustafson, Melissa Plets, Ian M. Thompson, Jr

Clin Cancer Res (2021) 27 (9): 2435–2441.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-2409

Published: 01 May 2021

View article

Includes: Supplementary data

Journal Articles

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

Clin Cancer Res (2021) 27 (7): 1967–1973.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-3587

Published: 01 April 2021

View article

Journal Articles

The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures

Clin Cancer Res (2020) 26 (15): 4018–4030.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-3416

Published: 03 August 2020

View article

Includes: Supplementary data

Journal Articles

Abstract IA03: Molecular subtypes of bladder cancer: Toward a more granular description of cancer heterogeneity

David J. McConkey, Woonyoung Choi, Colin P.N. Dinney, Arlene Siefker-Radtke, Bogdan Czerniak

Clin Cancer Res (2020) 26 (15_Supplement): IA03.

DOI: https://doi.org/10.1158/1557-3265.BLADDER19-IA03

Published: 03 August 2020

View article

Journal Articles

Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials

Clin Cancer Res (2020) 26 (4): 882–891.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-1920

Published: 14 February 2020

View article

Includes: Supplementary data

Journal Articles

Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer

Max Kates, Abhijit Date, Takahiro Yoshida, Umara Afzal, Pranjali Kanvinde, Taarika Babu, Nikolai A. Sopko, Hotaka Matsui, Noah M. Hahn, David J. McConkey, Alexander Baras, Justin Hanes, Laura Ensign, Trinity J. Bivalacqua

Clin Cancer Res (2017) 23 (21): 6592–6601.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-1082

Published: 31 October 2017

View article

Includes: Supplementary data

Journal Articles

Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells

Edmund Chiong, I-Ling Lee, Ali Dadbin, Anita L. Sabichi, Loleta Harris, Diana Urbauer, David J. McConkey, Rian J. Dickstein, Tiewei Cheng, H. Barton Grossman

Clin Cancer Res (2011) 17 (9): 2863–2873.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-3202

Published: 01 May 2011

View article

Includes: Supplementary data

Journal Articles

New Strategies in Muscle-Invasive Bladder Cancer: On the Road to Personalized Medicine

Jay B. Shah, David J. McConkey, Colin P.N. Dinney

Clin Cancer Res (2011) 17 (9): 2608–2612.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-2770

Published: 01 May 2011

View article

Journal Articles

Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma

Gonzalo Lopez, Juehui Liu, Wenhong Ren, Wei Wei, Suizhao Wang, Guy Lahat, Quan-Sheng Zhu, William G. Bornmann, David J. McConkey, Raphael E. Pollock, Dina C. Lev

Clin Cancer Res (2009) 15 (10): 3472–3483.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-2714

Published: 18 May 2009

View article

Journal Articles

Delta-Crystallin Enhancer Binding Factor 1 Controls the Epithelial to Mesenchymal Transition Phenotype and Resistance to the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Human Head and Neck Squamous Cell Carcinoma Lines

Yasmine Haddad, Woonyoung Choi, David J. McConkey

Clin Cancer Res (2009) 15 (2): 532–542.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-1733

Published: 15 January 2009

View article

Journal Articles

Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells

Xue Pan, Thiruvengadam Arumugam, Tameyoshi Yamamoto, Pavel A. Levin, Vijaya Ramachandran, Baoan Ji, Gabriel Lopez-Berestein, Pablo E. Vivas-Mejia, Anil K. Sood, David J. McConkey, Craig D. Logsdon

Clin Cancer Res (2008) 14 (24): 8143–8151.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-1539

Published: 15 December 2008

View article

Includes: Supplementary data

Journal Articles

Human Mena^+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines

Maria S. Pino, Michele Balsamo, Francesca Di Modugno, Marcella Mottolese, Massimo Alessio, Elisa Melucci, Michele Milella, David J. McConkey, Ulrike Philippar, Frank B. Gertler, Pier Giorgio Natali, Paola Nisticò

Clin Cancer Res (2008) 14 (15): 4943–4950.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-0436

Published: 01 August 2008

View article

Journal Articles

Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

Peter C. Black, Gordon A. Brown, Teruo Inamoto, Marissa Shrader, Ameeta Arora, Arlene O. Siefker-Radtke, Liana Adam, Dan Theodorescu, Xifeng Wu, Mark F. Munsell, Menashe Bar-Eli, David J. McConkey, Colin P.N. Dinney

Clin Cancer Res (2008) 14 (5): 1478–1486.

DOI: https://doi.org/10.1158/1078-0432.CCR-07-1593

Published: 03 March 2008

View article

Journal Articles

Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy

Kelly N. Blehm, Philippe E. Spiess, Jolanta E. Bondaruk, Melanie E. Dujka, Gabriel J. Villares, Yi-jue Zhao, Oliver Bogler, Kenneth D. Aldape, H. Barton Grossman, Liana Adam, David J. McConkey, Bogdan A. Czerniak, Colin P. Dinney, Menashe Bar-Eli

Clin Cancer Res (2006) 12 (15): 4671–4677.

DOI: https://doi.org/10.1158/1078-0432.CCR-06-0407

Published: 09 August 2006

View article

Journal Articles

Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668

Darren W. Davis, Ryan Takamori, Chandrajit P. Raut, Henry Q. Xiong, Roy S. Herbst, Walter M. Stadler, John V. Heymach, George D. Demetri, Asif Rashid, Yu Shen, Sijin Wen, James L. Abbruzzese, David J. McConkey

Clin Cancer Res (2005) 11 (2): 678–689.

DOI: https://doi.org/10.1158/1078-0432.678.11.2

Published: 08 February 2005

View article

Journal Articles

Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

John V. Heymach, Jayesh Desai, Judith Manola, Darren W. Davis, David J. McConkey, David Harmon, David P. Ryan, Geraldine Goss, Travis Quigley, Annick D. Van den Abbeele, Stuart G. Silverman, Susan Connors, Judah Folkman, Christopher D. M. Fletcher, George D. Demetri

Clin Cancer Res (2004) 10 (17): 5732–5740.

DOI: https://doi.org/10.1158/1078-0432.CCR-04-0157

Published: 08 September 2004

View article

Journal Articles

Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors

Darren W. Davis, Yu Shen, Nizar A. Mullani, Sijin Wen, Roy S. Herbst, Michael O’Reilly, James L. Abbruzzese, David J. McConkey

Clin Cancer Res (2004) 10 (1): 33–42.

DOI: https://doi.org/10.1158/1078-0432.CCR-0736-3

Published: 20 January 2004

View article

Journal Articles

Effects of the Proteasome Inhibitor, Bortezomib, on Apoptosis in Isolated Lymphocytes Obtained from Patients with Chronic Lymphocytic Leukemia

Jessica C. Pahler, Stacey Ruiz, Irina Niemer, Leslie R. Calvert, Michael Andreeff, Michael Keating, Stefan Faderl, David J. McConkey

Clin Cancer Res (2003) 9 (12): 4570–4577.

Published: 10 October 2003

View article

Journal Articles

Fully Human Anti-Interleukin 8 Antibody Inhibits Tumor Growth in Orthotopic Bladder Cancer Xenografts via Down-Regulation of Matrix Metalloproteases and Nuclear Factor-κB

Badar M. Mian, Colin P. N. Dinney, Carlos E. Bermejo, Paul Sweeney, Carmen Tellez, X. D. Yang, Jean M. Gudas, David J. McConkey, Menashe Bar-Eli

Clin Cancer Res (2003) 9 (8): 3167–3175.

Published: 11 August 2003

View article

Journal Articles

Nuclear Factor-κB Mediates Angiogenesis and Metastasis of Human Bladder Cancer through the Regulation of Interleukin-8

Takashi Karashima, Paul Sweeney, Ashish Kamat, Suyun Huang, Sun J. Kim, Menashe Bar-Eli, David J. McConkey, Colin P. N. Dinney

Clin Cancer Res (2003) 9 (7): 2786–2797.

Published: 01 July 2003

View article

NARROW

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures

Abstract IA03: Molecular subtypes of bladder cancer: Toward a more granular description of cancer heterogeneity

Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials

Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer

Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells

New Strategies in Muscle-Invasive Bladder Cancer: On the Road to Personalized Medicine

Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma

Delta-Crystallin Enhancer Binding Factor 1 Controls the Epithelial to Mesenchymal Transition Phenotype and Resistance to the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Human Head and Neck Squamous Cell Carcinoma Lines

Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells

Human Mena^+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines

Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells

Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy

Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668

Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors

Effects of the Proteasome Inhibitor, Bortezomib, on Apoptosis in Isolated Lymphocytes Obtained from Patients with Chronic Lymphocytic Leukemia

Fully Human Anti-Interleukin 8 Antibody Inhibits Tumor Growth in Orthotopic Bladder Cancer Xenografts via Down-Regulation of Matrix Metalloproteases and Nuclear Factor-κB

Nuclear Factor-κB Mediates Angiogenesis and Metastasis of Human Bladder Cancer through the Regulation of Interleukin-8

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only